U.S. Pharmaceutical Tariffs Take Effect July 31: What Changes
Tariffs on some imported patented drugs begin July 31, but generic medicines and biosimilars remain excluded as companies face different rates and deadlines.
The first phase of the Trump administration’s tariffs on certain imported patented pharmaceuticals and related ingredients takes effect at 12:01 a.m. Eastern on July 31, 2026.
The policy does not apply to every prescription drug or every pharmaceutical import. The initial phase covers applicable products from the companies listed in Annex III of an April 2 presidential proclamation. The annex lists 17 companies, including AbbVie, Amgen, AstraZeneca, Eli Lilly, Pfizer, Regeneron and Sanofi. Other covered companies face a later effective date of Sept. 29.
What changes on July 31
The proclamation generally establishes a 100% tariff on covered patented pharmaceuticals and associated pharmaceutical ingredients. The July 31 phase applies to qualifying goods from the Annex III companies, while the proclamation and its annexes set out the product categories, company-specific agreements and tariff treatment that determine how each import is handled.
Coverage is tied to the proclamation’s Harmonized Tariff Schedule categories and defined pharmaceutical products. An imported medicine is not automatically covered simply because it is a prescription drug or because it is made outside the United States. Annex IV separately lists tariff codes subject to a zero rate under the pharmaceutical action.
Why some companies may pay less
The general 100% rate is not the only possible treatment. The proclamation provides pathways for lower or zero tariffs under specified conditions, including approved plans to expand or relocate production in the United States, most-favored-nation pricing agreements, trade agreements and other negotiated commitments.
Companies with approved onshoring plans can qualify for a 20% rate, which the proclamation says is scheduled to rise to 100% on April 2, 2030. Products from Japan, the European Union, South Korea, and Switzerland and Liechtenstein generally receive a 15% rate, while products from the United Kingdom receive a 10% rate subject to the agreement described in the proclamation.
Companies with qualifying onshoring and MFN pricing agreements can receive a zero rate through Jan. 20, 2029. The lowest applicable rate generally controls when more than one tariff treatment could apply.
Specialty products and current exclusions
The proclamation provides for zero-rate treatment for certain specialty products when its conditions are met. The categories include orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, medical countermeasures related to chemical, biological, radiological and nuclear threats, and qualifying animal-health products.
Those specialty categories are not unconditional exemptions. The proclamation requires the Commerce secretary, in consultation with other officials, to determine that the products come from a jurisdiction with a qualifying trade and security framework or meet an urgent U.S. health need. The administration must publish a Federal Register notice when it makes that determination.
Generic pharmaceuticals, biosimilars and their associated ingredients are not subject to these tariffs at this time. The proclamation calls for monitoring and a later review of generic-drug imports; that is not the same as a final tariff rule.
Why the administration imposed the tariffs
The White House says the policy is a national-security and supply-chain measure intended to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign production. The proclamation says the administration’s investigation found that imports of pharmaceuticals and associated ingredients threatened to impair national security. The administration has also linked tariff preferences to negotiations over pricing and investment in U.S. facilities.
Those are the administration’s stated findings and objectives. They do not, by themselves, establish that the tariffs will produce more domestic capacity, improve supply security or lower prices.
What consumers and the health system could see
The immediate effect on pharmacy prices is uncertain. A tariff is charged at the import stage, but the final effect can depend on how manufacturers, wholesalers, insurers, hospitals and pharmacies divide, absorb or pass along the added cost.
Companies could adjust sourcing, inventory levels, production plans or prices. Hospitals and pharmacies may face additional purchasing and supply-chain decisions, while insurers could evaluate whether higher acquisition costs affect premiums, reimbursements or coverage negotiations. None of those outcomes is guaranteed, and there is not yet evidence that patients will see an immediate increase at the counter.
Independent pharmaceutical-supply-chain analysts have also raised broader questions about drug shortages, industry concentration, regulatory constraints and affordability. Those concerns are expert analysis, not official findings that the tariffs will cause shortages or higher prices.
What happens next
The next major date is Sept. 29, when the later phase for other covered companies is scheduled to begin. In the meantime, company-specific agreements, approved onshoring plans, Federal Register notices, customs guidance and enforcement decisions will determine how the policy applies in practice.
For consumers and health systems, the most useful signals will be changes in product availability, insurer or hospital cost notices, manufacturer pricing decisions and new administration guidance. The central point for now is narrow but important: the July 31 tariff applies to a defined group of patented pharmaceutical products and companies, not to all medicines entering the United States.
Sources
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.
